

Selection of MOMENTUM peer-reviewed publications–May 2024



Safety and Tolerability of Online Adaptive High-Field Magnetic Resonance–Guided Radiotherapy

JAMA Netw Open. 2024;7(5):e2410819. Westerhoff JM, Daamen LA, Christodouleas JP, Blezer ELA, Choudhury A, Westley RL, Erickson BA, Fuller CD, Hafeez S, van der Heide UA, Intven MPW, Kirby AM, Lalondrelle S, Minsky BD, Mook S, Nowee ME, Marijnen CAM, Orrling KM, Sahgal A, Schultz CJ, Faivre-Finn C, Tersteeg RJHA, Tree AC, Tseng CL, Schytte T, Silk DM, Eggert D, Luzzara M, van der Voort van Zyp JRN, Verkooijen HM, Hall WA
doi:10.1001/jamanetworkopen.2024.10819

Background and Purpose: The study evaluates the safety, tolerability, and technical feasibility of the 1.5T MR-Linac. It focuses on the adapt-to-shape (ATS) approach, which adjusts the radiation plan for each treatment session based on daily anatomical changes.

Materials and Methods: Adults with solid tumors treated with the 1.5-T MR-Linac from February 2019 to October 2021 were included in the MOMENTUM study. The data, collected across five countries, were analysed in August 2023. Treatments followed institutional care standards.

Results: The study included 1793 treatment courses for 1772 patients. The most frequently treated sites were the prostate, metastatic lymph nodes, and brain. The ATS strategy was applied in 58.6% of the treatments. The occurrence of acute high-grade toxic effects was low, with 1.4% of the entire cohort and only 0.4% among those treated with ATS experiencing such effects. Additionally, there were no reports of grade 4 or 5 toxic effects.

Conclusions: The 1.5T MR-Linac treatment was found to be safe and well-tolerated. Online adaptive radiotherapy was associated with a low risk of severe acute toxic effects, demonstrating its technical feasibility and potential benefits for patients with solid tumors.

Quality of life and clinical outcomes in rectal cancer patients treated on a 1.5T MR-Linac within the MOMENTUM study

Clin Transl Radiat Oncol. 2024;45:100721. Daamen L.A.; Westerhoff J.M.; Couwenberg A.M.; Braam P.M.; Rütten H.; den Hartogh M.D.; Christodouleas J.P.; Hall W.A.; Verkooijen H.M.; Intven M.P.W.. doi: 10.1016/j.ctro.2023.100721

Background and purpose: This study investigated quality of life (QoL) and clinical outcomes in rectal cancer patients treated with MR-guided short-course radiation therapy (SCRT) using a 1.5T MR-Linac during the initial 12 months after treatment.

Methods: Patients receiving 25 Gy SCRT in five fractions for curative intent were included. Toxicity and QoL were assessed, and clinical and pathological complete response rates were calculated. Dosimetric parameters were compared to standard non-adaptive treatment plans.

Results: Among 172 patients, complete response rates were observed at three, six, and twelve months. Diarrhea, blood and mucus in stool, and anxiety were improved after 12 months.

Conclusions: High-field MR-guided SCRT for rectal cancer is associated with improved symptom management and functioning one year after treatment.

[MRI-guided radiotherapy in twenty fractions for localised prostate cancer; results from the MOMENTUM study](#)

Clin Transl Radiat Oncol. 2024;46:100742. Sritharan Kobika; Daamen Lois; Pathmanathan Angela; Schytte Tine; Pos Floris; ChoudhuryAnanya; van der Voort van Zyp Jochem; Kerkmeijer Linda; Hall William; Hall Emma; Verkooijen Helena; Herbert Trina; Hafeez Shaista; Mitchell Adam; Tree Alison. doi: 10.1016/j.ctro.2024.100742

Background and Purpose: This study evaluated MRgRT for localized prostate cancer using a 1.5 T MR-Linac. Two-year toxicity outcomes, early biochemical response, and patient-reported outcomes were assessed.

Methods: Patients enrolled in the MOMENTUM study received radical treatment with 60 Gy in 20 fractions. PSA levels and toxicity data were measured at follow-up visits. Patient-reported outcomes were also collected.

Results: 146 patients received MRgRT for localized prostate cancer. Gastro-intestinal (GI) toxicity was 3% at three months, and genitourinary (GU) toxicity was 7%. Median PSA decreased at 12 months. Quality of life declined initially but improved by 24 months.

Conclusion: Online MRgRT with a 1.5 T MR-Linac is feasible and is associated with low rates of toxicity.

[Interim toxicity analysis from the randomised HERMES trial of 2- and 5-fraction MRI-guided adaptive prostate radiotherapy.](#)

Int J Radiat Oncol Biol Phys. 2023. Westley DRL; Biscombe K; Dunlop A; Mitchell A; Oelfke U; Nil S; Murray J; Pathmanathan A; Hafeez S; Parker C; Ratnakumaran R; Alexander S; Herbert T; Hall E; Tree AC. doi: 10.1016/j.ijrobp.2023.09.032

Background and Purpose: Ultra-hypofractionated radiotherapy is effective for localized prostate cancer. Boosting the visible intraprostatic tumor can improve biochemical disease-free survival without significant toxicity.

Methods: The HERMES trial enrolled men with intermediate or lower high-risk prostate cancer. Patients received either 36.25 Gy in 5 fractions over 2 weeks or 24 Gy in 2 fractions over 8 days, with an integrated boost to the MRI-visible tumor. Acute genitourinary (GU) toxicity was the primary endpoint.

Findings: In this interim analysis, grade 2 GU toxicity was reported in 10% (5-fraction group) and 20% (2-fraction group). No grade 3 or higher toxicities were observed.

Interpretation: As the rate of GU toxicity in the 2-fraction and 5-fraction study groups was below the pre-specified threshold the study will continue patient recruitment.

Clinical outcomes after online adaptive MR-guided stereotactic body radiotherapy for pancreatic tumors on a 1.5 T MR-linac

Front Oncol. 2023;13:1040673. Eijkelenkamp Hidde; Grimbergen Guus; Daamen Lois; Heerkens Hanne; van de Ven Saskia; Mook Stella; Meijer Gert; Molenaar Izaak; van Santvoort Hjalmar; Paulson Eric; Erickson Beth; Verkooijen Helena; Hall William; Intven Martijn. doi: 10.3389/fonc.2023.1040673

Background and Purpose: Online adaptive MRgRT is a promising treatment for pancreatic cancer. However, clinical outcomes have been reported on a small scale, often from single institutes and clinical trials. This study presents outcomes of a large international cohort of patients with (peri)pancreatic tumors treated with online adaptive MRgRT.

Methods: Patients with (peri)pancreatic tumors were treated on a 1.5T MR-linac in two large-volume centers. Acute and late toxicity were assessed, and quality of life (QoL) was evaluated using the EORTC QLQ-C30 questionnaire. Overall survival was calculated using Kaplan–Meier analysis.

Results: Among 80 patients, 357 of 358 fractions were delivered as planned. Acute grade 3–4 toxicity occurred in 5% (hypofractionated MRgRT), and late grade 3–4 toxicity in 12%. Six patients died within 3 months after MRgRT. QoL remained stable from baseline to 3 months follow-up.

Conclusion: Online adaptive MRgRT for (peri)pancreatic tumors is well-tolerated and were associated with limited grade 3-4 toxicity and stable QoL at 3 months follow-up.

Online adaptive MR-guided stereotactic radiotherapy for unresectable malignancies in the upper abdomen using a 1.5T MR-linac.

Acta Oncol. 2022;61:111-115. Daamen LA; de Mol van Otterloo SR; van Goor IWJM; Eijkelenkamp H; Erickson BA; Hall WA; Heerkens HD; Meijer GJ; Molenaar IQ; van Santvoort HC; Verkooijen HM; Intven MPW. doi: 10.1080/0284186X.2021.2012593

Background and Purpose: Online adaptive MR-guided radiotherapy enables stereotactic body radiation therapy (SBRT) for upper abdominal tumors. This study evaluated the feasibility of MR-guided SBRT on a 1.5 T MR-linac in patients with unresectable upper abdominal malignancies.

Methods: Patients treated at UMC Utrecht were assessed. Feasibility was defined as an on-table time interval of ≤ 60 minutes for $>75\%$ of delivered fractions and completion of $>95\%$ of scheduled fractions. Acute toxicity was evaluated at 3 months follow-up.

Results: Twenty-five patients received 35 Gy (n=4) or 40 Gy (n=21) in five fractions over 2 weeks. Adapted treatment was completed within 1 hour for 84% of fractions. No acute grade 3 or higher toxicity was reported. Pain alleviation occurred in 11 out of 13 patients.

Discussion: Online adaptive MR-guided SBRT on a 1.5 T MR-linac is feasible and well-tolerated for unresectable upper abdominal malignancies. Further dose escalation and comparative studies are needed to determine optimal radiation doses.

First multicentre experience of SABR for lymph node and liver oligometastatic disease on the unity MR-Linac.

Tech Innov Patient Support Radiat Oncol. 2022;22:50-54. Janssen TM; Aitken K; Alongi F; Barry A; Bernchou U; Boeke S; Hall WA; Hosni A; Kroon PS; Nachbar M; Saeed H; Jürgenliemk-Schulz IM; Schytte T; Verkooijen HM; Nowee ME. doi: 10.1016/j.tipsro.2022.04.005

The management of oligometastatic disease with MR guidance is an area of ongoing development. Since August 2018, patients have been receiving treatment using a 1.5 Tesla MR-Linac (MRL). In this study, current workflows and practice standards from seven institutions for the initial treatment of patients with lymph node and liver metastases are shared.

Magnetic Resonance-Guided Adaptive Radiation therapy for Prostate Cancer: The First Results from the MOMENTUM study-An International Registry for the Evidence-Based Introduction of Magnetic Resonance-Guided Adaptive Radiation Therapy.

Pract Radiat Oncol. 2022. Teunissen FR; Willigenburg T; Tree AC; Hall WA; Choi SL; Choudhury A; Christodouleas JP; de Boer JCJ; Groot-van Breugel EN; Kerkmeijer LGW; Pos FJ; Schytte T; Vesprini D; Verkooijen HM; Voort van Zyp JRNv. doi: 10.1016/j.prro.2022.09.007

Purpose: MR-guided radiotherapy (MRgRT) is a novel technique for treating localized prostate cancer. We present 12-month outcomes for the first patients treated within the international MOMENTUM study using a 1.5T MR-Linac system with ultrahypofractionated radiation therapy (RT).

Methods and Materials: Patients receiving 5 × 7.25 Gy were evaluated. Prostate-specific antigen levels, physician-reported toxicity, and patient-reported outcomes were recorded at baseline and at 3, 6, and 12 months of follow-up (FU). Comparative statistics were used to compare outcomes between baseline and FU.

Results: The study included 425 patients with localized prostate cancer (11.4% low-risk, 82.0% intermediate-risk, and 6.6% high-risk). Median prostate-specific antigen levels significantly declined to 1.2 ng/mL and 0.1 ng/mL at 12 months FU for the non-androgen deprivation therapy (ADT) and ADT groups, respectively. Genitourinary and gastrointestinal toxicity peaked at 3 months FU (18.7% and 1.7% grade ≥2, respectively). The QLQ-PR25 questionnaire revealed significant deterioration in urinary domain score at all FU time points. For the non-ADT group, both physician- and patient-reported erectile function worsened significantly between baseline and 12 months FU.

Conclusions: Ultrahypofractionated MR-guided radiation therapy for localized prostate cancer using a 1.5T MR-Linac is effective and safe. Genitourinary and gastrointestinal toxicity was highest at 3 months FU and erectile dysfunction was significantly increased at 12 months follow-up. These data inform patient education and future study design.

Clinical implementation and feasibility of long-course fractionated MR-guided chemoradiotherapy for patients with esophageal cancer: An R-IDEAL stage 1b/2a evaluation of technical innovation.

Clin Transl Radiat Oncol. 2022;34:82-89. Boekhoff MR; Bouwmans R; Doornaert PAH; Intven MPW; Lagendijk JJW; van Lier ALHMW; Rasing MJA; van de Ven S; Meijer GJ; Mook S. doi: 10.1016/j.ctro.2022.03.008

Purpose: This study describes the workflow and feasibility of long-course fractionated online adaptive MR-guided chemoradiotherapy with reduced CTV-to-PTV margins on the 1.5T MR-Linac for patients with esophageal cancer.

Methods: Patients undergoing chemoradiation were treated on a 1.5T MR-Linac. Daily MR images were used for contour adaptation. An isotropic CTV-to-PTV margin of 6 mm was applied. Feasibility and patient tolerability were defined. Dosimetric parameters were compared to standard non-adaptive treatment plans.

Results: Nine patients received chemoradiation. Most fractions were successfully delivered on the MR-Linac. Daily adapted MR-Linac plans maintained target coverage while reducing dose to organs-at-risk.

Conclusion: Daily online adaptive fractionated chemoradiotherapy with reduced PTV margins is moderately feasible for esophageal cancer, resulting in better sparing of heart and lungs.

Patterns of Care, Tolerability, and Safety of the First Cohort of Patients Treated on a Novel High-Field MR-Linac Within the MOMENTUM Study: Initial Results From a Prospective Multi-Institutional Registry.

Int J Radiat Oncol Biol Phys. 2021;111:867-875. Christodouleas JP; Blezer ELA; Akhiat H; Brown K; Choudhury A; Eggert D; Erickson BA; Daamen LA; Faivre-Finn C; Fuller CD; Goldwein J; Hafeez S; Hall E; Harrington KJ; van der Heide UA; Huddart RA; Intven MPW; Kirby AM; Lalondrelle S; McCann C; Minsky BD;. doi: 10.1016/j.ijrobp.2021.07.003

Purpose: High-field MR-Linacs have the potential to revolutionize radiation therapy. We report the initial experience within the MOMENTUM Study, a prospective international registry of the MR-Linac Consortium.

Methods and Materials: Patients from 7 institutions in 4 countries were included. Descriptive statistics were used to describe patterns of care, tolerability, and safety. Acute toxicity was assessed within 3 months after treatment.

Results: A total of 943 patients participated in the study. Most patients were male (79%) with a median age of 68 years. The most common indications were prostate, oligometastatic lymph node, brain, and rectal cancers. Six patients discontinued MR-Linac treatments, but none due to inability to tolerate repeated high-field MRI. Acute toxicity related to radiation was minimal.

Conclusions: High-field MR-Linac treatment was well-tolerated, and acute radiation toxicity was encouraging.



Hope for everyone
dealing with cancer.

Elekta AB

Box 7593
SE- 103 93
Stockholm, Sweden
T +46 8 587 254 00

Latin America, South America

T +55 11 5054 4550

Asia Pacific

T +65 6221 2322

Turkey, India, Middle East, Africa

T +90 216 4743500

Japan

T +81 3 6722 3808

North America

T +1 770 300 9725

China

T +86 10 5669 2800

For further information please contact your local Elekta office.
Details can be found at [elekta.com/offices](https://www.elekta.com/offices).

 [elekta.com](https://www.elekta.com)  [/elekta](https://www.facebook.com/elekta)

 [@elekta](https://twitter.com/elekta)  [/company/elekta](https://www.linkedin.com/company/elekta)

[elekta.com](https://www.elekta.com)

LPCMRL240412 v2 © The Elekta Group 2024. All Rights Reserved. Elekta and all referenced trademarks are property of the Elekta Group. Products not available in all markets.